Acumen Pharmaceuticals, Inc.
A complete Wall Street Score is unavailable because required model components are missing. Missing model components: revenue, financial, Buffett-style model component. These are scoring components, not a claim that the company has no assets or earnings. Missing inputs are not zero and do not by themselves make this a weak company. Available financial statements and source-backed research remain visible.
ABOS · Price history
Price at last available close
$2.38
+$0.13 (+5.78%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Acumen Pharmaceuticals, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers.
How they make money
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and entering into strategic research and development collaborations to fund the clinical advancement of its proprietary therapeutic candidates for Alzheimer's disease.
Products & services
The company is developing sabirnetug (ACU193), a humanized monoclonal antibody designed to target toxic soluble amyloid-beta oligomers for the treatment of Alzheimer's disease.
Brands & revenue mix
Lead therapeutic candidate currently in Phase 2 clinical development.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed.Source
Business relationships & partnerships
- JCR Pharmaceuticals Co. Ltd. — A collaboration, option, and license agreement to develop an Aβ oligomer-targeted Enhanced Brain Delivery (EBD) therapy for Alzheimer's disease using JCR's J-Brain Cargo technology.Source
Competitors
- Biogen Inc. — Develops and markets therapies for Alzheimer's disease, including monoclonal antibodies targeting amyloid-beta.Source
- Eli Lilly and Company — Develops and markets therapies for Alzheimer's disease, including monoclonal antibodies targeting amyloid-beta.Source
- Eisai Co., Ltd. — Develops and markets therapies for Alzheimer's disease, including monoclonal antibodies targeting amyloid-beta.Source
Strengths
Risks
- History of operating losses and expectation of continued losses for the foreseeable future.Source
- Significant dependence on the success of a single lead product candidate, sabirnetug.Source
- Risks associated with clinical trial outcomes, regulatory approval processes, and reliance on third-party manufacturers.Source
Sources
Company-specific research
Questions worth answering for ABOS
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can ABOS fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is ABOS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for ABOS to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ABOS's current valuation?
- •What does the current corporate distress warning mean for the reliability or interpretation of ABOS's score?
Essential Investment Snapshot
Market Cap
$172.1M
P/E Ratio
-1.4
EPS
$-1.64
52-Week High
$3.60
52-Week Low
$1.50
Beta
0.33
Analyst Target
$7.00
Shares Outstanding
60.6M
Total Debt
$31.6M
Dividend
No current dividend
Liquidation Value / Share
$0.95
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ABOS
Detected from reported data — verify before acting.MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Going-concern warning
A recent SEC filing contains explicit going-concern language. Wall Street Score is capped at 15 until the distress condition is resolved in later filings.
Supporting filingCRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingHistorical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Debt service risk
Interest coverage is low (~-29.3x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on ABOS.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary focus on toxic soluble amyloid-beta oligomers (AβOs) as a therapeutic target.
- +Strategic partnership with JCR Pharmaceuticals to enhance brain delivery of therapies.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of continued losses for the foreseeable future.
- −Significant dependence on the success of a single lead product candidate, sabirnetug.
- −Risks associated with clinical trial outcomes, regulatory approval processes, and reliance on third-party manufacturers.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$2.38
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Cost of Revenue | $46K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Gross Profit | -$46K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Research & Development | $86.8M | $104.9M | $93.8M | $42.3M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $18.6M | $18.9M | $20.2M | $18.8M | ···· | ···· | ···· | ···· |
| Operating Expenses | $105.4M | $123.8M | $114.0M | $61.1M | ···· | ···· | ···· | ···· |
| EBITDA | -$100.4M | -$116.9M | -$98.1M | -$51.6M | ···· | ···· | ···· | ···· |
| Operating Income | -$105.4M | -$123.8M | -$114.0M | -$61.1M | ···· | ···· | ···· | ···· |
| Interest Expense | $4.3M | $4.2M | $4.1M | $581K | ···· | ···· | ···· | ···· |
| Income Before Tax | -$105.0M | -$121.3M | -$102.3M | -$52.4M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Net Income | -$105.0M | -$121.3M | -$102.3M | -$52.4M | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.64 | $-2.00 | $-1.71 | $-1.08 | ···· | ···· | ···· | ···· |
| Basic Shares | 72.25M | 60.56M | 60.01M | 48.49M | ···· | ···· | ···· | ···· |
| Diluted Shares | 72.25M | 60.56M | 60.01M | 48.61M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.45
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+4.9%
Cash Change
+61.5%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 33.8%. Cash increased 61.5%. Total debt increased 4.9%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals Q3 Earnings Call Highlights
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Rumor Mill · ABOS
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial